75 results match your criteria: "Insure (Institute for Translational Cardiac Surgery)[Affiliation]"

Article Synopsis
  • The study examined differences in echocardiographic assessments of native and bioprosthetic aortic valves between core laboratories and clinical centers, finding clinically relevant discrepancies.
  • Data was collected from the PERIGON trial, which involved patients undergoing surgical aortic valve replacement, and involved comparing echocardiographic results from centers to independent analysis by a core lab.
  • Results showed that while some continuous measurements had high agreement (around 0.90), there were notable variances, particularly in left ventricular outflow tract area and stroke volume, indicating the need for standardized evaluation practices.
View Article and Find Full Text PDF
Article Synopsis
  • Atrioventricular valve regurgitation is a significant issue in patients with univentricular hearts and poses challenges for surgical repairs, which are crucial for improving outcomes.
  • A study reviewed surgeries from 1994 to 2021 on 202 patients with univentricular hearts, finding that 15.8% needed atrioventricular valve surgery, with varying outcomes based on valve types and surgical techniques used.
  • Although the surgeries had low immediate and long-term mortality rates (3.1% and 9.7% respectively), a notable number of patients (30.9%) required reoperations within 10 years.
View Article and Find Full Text PDF

Background: Clinical consequences of prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR) is currently in the focus of clinical research. Patients with small aortic annulus are at higher risk to display PPM. Data on incidence and clinical consequences of PPM after TAVR with either balloon-expandable (BEV) or self-expanding (SEV) transcatheter heart valves in small aortic annulus are sparse.

View Article and Find Full Text PDF

Background: Transcatheter mitral valve replacement (TMVR) using dedicated devices is an alternative therapy for high-risk patients with symptomatic mitral regurgitation (MR).

Aims: This study aimed to assess the 2-year outcomes and predictors of mortality in patients undergoing TMVR from the multicentre CHOICE-MI Registry.

Methods: The CHOICE-MI Registry included consecutive patients with symptomatic MR treated with 11 different dedicated TMVR devices at 31 international centres.

View Article and Find Full Text PDF

Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation: A Propensity Score-Matched Comparison.

Circ Cardiovasc Interv

June 2023

Cardiovascular Research Foundation, New York City, NY (S.L., D.J.C., A.C., A.S., Z.Z., Y.L., B.R., J.F.G.).

Background: Transcatheter mitral valve replacement (TMVR) is an emerging therapeutic alternative for patients with secondary mitral regurgitation (MR). Outcomes of TMVR versus guideline-directed medical therapy (GDMT) have not been investigated for this population. This study aimed to compare clinical outcomes of patients with secondary MR undergoing TMVR versus GDMT alone.

View Article and Find Full Text PDF
Article Synopsis
  • Congenital heart disease (CHD) has a strong genetic component, yet previous research has struggled to pinpoint inherited risks due to limited analysis of common variants in small groups of people.
  • A large study involving 55,342 participants reanalyzed genetic data, identifying 16 new genetic locations associated with different types of CHD, including 12 rare variants with notable effects.
  • The findings indicate that while each type of CHD is heritable, they appear to have distinct genetic risks, underscoring the complexity of CHD genetics.
View Article and Find Full Text PDF

Introduction: Acute kidney injury (AKI) is a common complication after cardiac surgery (CS) and is associated with adverse short-term and long-term outcomes. Alpha-1-microglobulin (A1M) is a circulating glycoprotein with antioxidant, heme binding and mitochondrial-protective mechanisms. RMC-035 is a modified, more soluble, variant of A1M and has been proposed as a novel targeted therapeutic protein to prevent CS-associated AKI (CS-AKI).

View Article and Find Full Text PDF
Article Synopsis
  • The study compared outcomes of transcatheter mitral valve replacement (TMVR) and mitral valve transcatheter edge-to-edge repair (M-TEER) in treating secondary mitral regurgitation (SMR).
  • A total of 262 patients underwent TMVR, while 1,065 received M-TEER, with matched cohorts analyzed for outcomes over one year.
  • Results showed TMVR led to better reduction in mitral regurgitation and improved symptoms compared to M-TEER, but showed a tendency for higher early mortality without significant differences in mortality beyond 30 days.
View Article and Find Full Text PDF

Background:  We aimed to compare hemodynamic performance of the Avalus (Medtronic) and the Perimount Magna Ease (PME, Edwards Lifesciences) bioprosthesis up to 5 years by serial echocardiographic examinations.

Methods:  In patients undergoing aortic valve replacement, 58 received PME prostheses between October 2007 and October 2008, and another 60 received Avalus prostheses between October 2014 and November 2015. To ensure similar baseline characteristics, we performed a propensity score matching based on left ventricular ejection fraction, age, body surface area, and aortic annulus diameter measured by intraoperative transesophageal echocardiography.

View Article and Find Full Text PDF

Objectives: Calcified or fibrotic cusps in patients with bicuspid aortic valves and aortic regurgitation complicate successful aortic valve (AV)-repair. Aortic valve neocuspidization (AVNeo) with autologous pericardium offers an alternative treatment to prosthetic valve replacement. We compared patients with regurgitant bicuspid valves undergoing AV-repair or AVNeo.

View Article and Find Full Text PDF

Accidental injury to the cardiac conduction system (CCS), a network of specialized cells embedded within the heart and indistinguishable from the surrounding heart muscle tissue, is a major complication in cardiac surgeries. Here, we addressed this unmet need by engineering targeted antibody-dye conjugates directed against the CCS, allowing for the visualization of the CCS in vivo following a single intravenous injection in mice. These optical imaging tools showed high sensitivity, specificity, and resolution, with no adverse effects on CCS function.

View Article and Find Full Text PDF

Introduction: Aortic valve neocuspidization (AVNeo) for trileaflet aortic valve reconstruction using autologous pericardium (Ozaki procedure) depicts an encouraging new technique for the surgical treatment of aortic valve pathologies. The current study analyzes the early hemodynamic outcome of AVneo compared with surgical aortic valve replacement (SAVR) using the Abbott/St. Jude Trifecta aortic valve biological prostheses.

View Article and Find Full Text PDF

Surgical explantation of failed transcatheter heart valves: indications and results.

Heart Vessels

December 2022

Department of Cardiovascular Surgery, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Given the recent surge in transcatheter heart valve replacement (THVR), cardiac surgeons will surely face the challenge of eventual explantation. The aim of this study was to determine indications for reoperation, while exploring pertinent technical aspects and survival after THV explantation in a cohort originally deemed high risk or even inoperable. Between February 2008 and March 2019, 31 patients with failed transcatheter aortic valve replacement (TAVR) underwent surgical explantations at our facility.

View Article and Find Full Text PDF

Background: Isolated tricuspid valve endocarditis (TVE) is a rare disease which is managed medically in most patients. Only in specific cases, surgical intervention becomes necessary. Hence, data about surgical outcomes are sparse.

View Article and Find Full Text PDF

Background: Bioprosthetic valve fracturing (BVF) results in low gradients following valve-in-valve transcatheter aortic valve replacement (ViV-TAVR). For the commonly used Edwards PERIMOUNT valve data from bench-testing are lacking to provide technical specifications for successful BVF during ViV-TAVR.

Methods: Using four Perimount 19- and 21-mm valves, high-pressure balloon valvuloplasty with the True Dilatation Balloon Valvuloplasty Catheter and Atlas Gold PTA Dilatation Catheter was performed to analyze balloon-oversizing and pressure-thresholds to successfully achieve BVF.

View Article and Find Full Text PDF

Non-robotic minimally invasive mitral valve repair: a 20-year single-centre experience.

Eur J Cardiothorac Surg

October 2022

Department of Cardiovascular Surgery, German Heart Center Munich, Technical University Munich, Munich, Germany.

Objectives: Minimally invasive mitral valve repair (MVR) promises major advantages over median sternotomy regarding cosmetic results and faster recovery. However, the long-term functional outcome of minimally invasive MVR has been questioned by critics because the limited access may not exclusively promise high-quality repair. This study examines the long-term outcome regarding survival and reoperation rate.

View Article and Find Full Text PDF

Backround: Mitral valve (MV) repair in the case of a large anterior-posterior diameter and redundant valve tissue remains challenging and favors repair with a ring that exhibits a large anterior-posterior diameter. Compared to other available rings, the Medtronic Simulus annuloplasty ring shows the largest anterior-posterior diameter. This study reports for the first time mid-term results using this annuloplasty ring.

View Article and Find Full Text PDF

Objectives: We aimed to describe stroke and transient ischemic attacks (TIAs) after transcatheter aortic valve replacement (TAVR) and to identify associated risk factors.

Background: Stroke/TIA after TAVR is a major complication.

Methods: A total of 1919 concomitant patients underwent TAVR in a single center from 2007 to 2017.

View Article and Find Full Text PDF

Single-centre outcome of extracorporeal membrane oxygenation after the neonatal Norwood procedure.

Eur J Cardiothorac Surg

August 2022

Department of Congenital and Pediatric Heart Surgery, German Heart Center Munich, Technische Universität München, Munich, Germany.

Objectives: Despite improvements in the surgical management of the hypoplastic left heart syndrome and its variant, the Norwood procedure is still associated with substantial mortality and morbidity and extracorporeal membrane oxygenation support is required in some patients.

Methods: We reviewed patients with the Norwood procedure between 2007 and 2019. The primary end point of the study was mortality during extracorporeal membrane oxygenation.

View Article and Find Full Text PDF

Molecular signaling pathways in right ventricular impairment of adult patients after tetralogy of Fallot repair.

Cardiovasc Diagn Ther

December 2021

Department of Congenital Heart Defects and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany.

Background: Right ventricular impairment (RVI) secondary to altered hemodynamics contributes to morbidity and mortality in adult patients after tetralogy of Fallot (TOF) repair. The goal of this study was to describe signaling pathways contributing to right ventricular (RV) remodeling by analyzing over lifetime alterations of RV gene expression in affected patients.

Methods: RV tissue was collected at the time of cardiac surgery in 13 patients with a diagnosis of TOF.

View Article and Find Full Text PDF

Propensity matched analysis of vascular complications using integrated or expandable sheaths for TAVR.

Catheter Cardiovasc Interv

April 2022

Department of Cardiovascular Surgery, INSURE (Institute for Translational Cardiac Surgery), German Heart Center, TUM, Munich, Germany.

Objectives: Vascular access site complications increase morbidity and mortality in transcatheter aortic valve replacement (TAVR).

Background: Medtronic's EnVeo PRO® low-profile sheath concept and Edwards' expandable eSheath® aim to lower vascular trauma and access site complications. This study aims to compare Valve Academic Research Consortium (VARC)-3 defined access-related vascular complications using the two different transcatheter heart valve (THV) delivery concepts.

View Article and Find Full Text PDF

Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome.

iScience

January 2022

Department of Congenital Heart Defects and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, School of Medicine and Health, Munich 80636, Germany.

Childhood-onset myocardial hypertrophy and cardiomyopathic changes are associated with significant morbidity and mortality in early life, particularly in patients with Noonan syndrome, a multisystemic genetic disorder caused by autosomal dominant mutations in genes of the Ras-MAPK pathway. Although the cardiomyopathy associated with Noonan syndrome (NS-CM) shares certain cardiac features with the hypertrophic cardiomyopathy caused by mutations in sarcomeric proteins (HCM), such as pathological myocardial remodeling, ventricular dysfunction, and increased risk for malignant arrhythmias, the clinical course of NS-CM significantly differs from HCM. This suggests a distinct pathophysiology that remains to be elucidated.

View Article and Find Full Text PDF

Background: Tricuspid valve (TV) repair is the recommended treatment for severe functional tricuspid regurgitation (fTR) in patients undergoing left-sided surgery. For this purpose, a wide range of annuloplasty devices differing in form and flexibility are available. This study reports the results using a three-dimensional annuloplasty ring (Medtronic, Contour 3D Ring) for TV repair and analysis of risk factors.

View Article and Find Full Text PDF

Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.

N Engl J Med

January 2022

From the Division of Cardiac Surgery, Johns Hopkins School of Medicine, Baltimore (J.S.G.), and the Division of Cardiovascular Sciences (M.A.M., W.C.T.-P.), National Heart, Lung, and Blood Institute (N.O.J.), National Institutes of Health, Bethesda - both in Maryland; the Division of Cardiac Surgery, Western University, London Health Sciences Centre, London, ON (M.W.A.C.), and the Division of Cardiovascular Surgery, Toronto General Hospital and University of Toronto, Toronto (R.W.), Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC (P.V.), and Cardiovascular and Thoracic Surgery, Department of Surgery, University of Alberta, Edmonton (J.C.M.) - all in Canada; the Department of Cardiothoracic and Vascular Surgery, Deutsche Herzzentrum Berlin, the Department of Cardiovascular Surgery, Charité Universitätsmedizin Berlin, and DZHK (German Center for Cardiovascular Research), Berlin (V.F.), Technical University of Munich, School of Medicine and Health, the Department of Cardiovascular Surgery, Institute Insure (Institute for Translational Cardiac Surgery), German Heart Center Munich, and DZHK, Munich (M.K.), the Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg (L.C.), the Department of Cardiovascular Surgery, University Heart Center Freiburg, and Albert Ludwigs University Freiburg, Freiburg (F.B.), and Leipzig Heart Center, University of Leipzig, Leipzig (M.A.B.) - all in Germany; the Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai (J.R.O., A.J.M., E.A.R., S.R., E.G.M., K.O., M.E.M., E.B., A.C.G.) and the Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine (M.K.P.) - both in New York; the Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland (M.G.); the Department of Cardiac and Thoracic Surgery, Baylor Scott and White Health, Plano (M.J.M.), and American Heart Association, Dallas (M.J.) - both in Texas; the Department of Surgery, Division of Cardiac Surgery, Yale School of Medicine, New Haven, CT (A.G., M.K.); the Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University, Durham, NC (B.Y.); the Departments of Surgery and Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles (M.E.B.); the Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor (S.F.B., G.A.); the Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH (A.I.); and the Division of Cardiology, Massachusetts General Hospital (J.H.) and the Division of Cardiovascular Medicine, Brigham and Women's Hospital (P.T.O.) - both in Boston.

Background: Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation.

Methods: We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA).

View Article and Find Full Text PDF